Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

Benzinga Newsdesk www.benzinga.com Neutral 73.5%

Neg 0% Neu 73.5% Pos 0%

Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.